28.98
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$28.61
Offen:
$28.54
24-Stunden-Volumen:
1.89M
Relative Volume:
1.14
Marktkapitalisierung:
$5.14B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
14.86
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-1.24%
1M Leistung:
-5.31%
6M Leistung:
+0.78%
1J Leistung:
+18.84%
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALKS
Alkermes Plc
|
28.98 | 5.14B | 1.51B | 333.35M | 315.22M | 1.95 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-28 | Eingeleitet | Needham | Buy |
2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2025-03-04 | Hochstufung | UBS | Sell → Neutral |
2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
2024-11-05 | Hochstufung | Stifel | Hold → Buy |
2024-06-17 | Eingeleitet | TD Cowen | Buy |
2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
2024-02-20 | Herabstufung | UBS | Neutral → Sell |
2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-10-17 | Eingeleitet | UBS | Neutral |
2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
2022-04-22 | Fortgesetzt | Goldman | Buy |
2022-04-20 | Eingeleitet | Goldman | Buy |
2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
2021-12-01 | Eingeleitet | Citigroup | Neutral |
2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-02-06 | Eingeleitet | Mizuho | Neutral |
2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
2018-08-07 | Eingeleitet | Stifel | Hold |
2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus
Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha
Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize
Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says - MarketScreener
Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | A - GuruFocus
Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | ALKS Stock News - GuruFocus
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stoc - GuruFocus
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stock News - GuruFocus
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33 - marketscreener.com
Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narco - GuruFocus
Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narcolepsy Treatment | ALKS Stock News - GuruFocus
When (ALKS) Moves Investors should Listen - news.stocktradersdaily.com
Substance Abuse Treatment Market Size, Trends & Growth - openPR.com
Insider Sell: Christian Nichols Sells Shares of Alkermes PLC - GuruFocus
RBC Capital maintains Alkermes stock rating amid safety concerns By Investing.com - Investing.com Nigeria
GAMMA Investing LLC Grows Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Transcript : Alkermes plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders By Investing.com - Investing.com Nigeria
Alkermes at Goldman Sachs Healthcare: Strategic Moves in Sleep Disorders - Investing.com Australia
Alkermes To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award - Law360
Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Nanotechnology Drug Delivery Market Set to Witness Significant - openPR.com
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - The Malaysian Reserve
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - StreetInsider
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Cetera Investment Advisers Increases Stock Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus
Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - goSkagit
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus
Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com
Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus
Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus
Quantinno Capital Management LP Acquires New Position in Alkermes plc (NASDAQ:ALKS) - Defense World
Controlled Release Drug Delivery Market Generated - openPR.com
Bank of America Corp DE Trims Stake in Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):